Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Ongoing early phase trials for patients with MTC.
| Drug | Molecular Target | Phase | Eligibility | Clinical Trial ID |
|---|---|---|---|---|
| Regorafenib | BRAF, VAGFR1-3 PDGFRα/β, RET, KIT, FGFR1-2 | 2 | MTC | NCT02657551 |
| TPX-0046 | RET | 1/2 | RET altered tumors | NCT04161391 |
| TAS0953/HM06 | RET | 1/2 | RET altered tumors | NCT04683250 |
| GFRα4 CAR T Cells | GFRα4 | 1 | MTC | NCT04877613 |
Currently open early phase studies including the multi-target TKI regorafenib as well as next generation RET-targeting TKIs and the first CAR T-cell targeting MTC.
